Biomatter

Biomatter is a synthetic biology company that leverages AI-based technology for generative protein design, providing an Intelligent Architecture platform that enables precise sequence and structure-based redesign of existing proteins. The platform uses machine learning to generate novel protein sequences with desired functional properties, accelerating the discovery and optimization of proteins for various applications. Biomatter technology serves multiple sectors including therapeutics, agriculture, molecular biology tools, and food technology, enabling researchers and companies to design proteins with improved stability, activity, and specificity. The company approach combines deep learning models with structural biology expertise to navigate the vast protein sequence space efficiently. Founded in 2018 and headquartered in Vilnius, Lithuania, Biomatter has raised approximately $7.7 million in seed funding from investors including UVC Partners, Inventure, Practica Capital, Metaplanet, and 70Ventures.

Life Sciences Tech > Research & Development > Drug Discovery > Proteomics,

Biopharma Outsourcing > Diversified > Small Molecules & Peptides

College Wise > University of Warwick